Emergent Biosolutions Inc. · NYSE:EBS
Emergent Biosolutions — Q1 2020 Earnings Presentation
16 slides from Emergent Biosolutions's earnings presentation, Apr 30, 2020
Slide 1: 1Q20 Quarterly Supplement
1Q20 Quarterly Supplement April 30, 2020
Slide 2: Safe Harbor Statement
Safe Harbor Statement Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, our financial guidance and related pr
Slide 3: Overview & Current State of the Company
Overview & Current State of Robert G. Kramer the Company President and Chief Executive Officer
Slide 4: The universal response to COVID-19
The universal response to COVID-19 4 1Q20 QUARTERLY SUPPLEMENT
Slide 5: COVID-19 Response: CDMO
COVID-19 Response: Syed T. Husain CDMO Senior Vice President, CDMO Business Unit Head
Slide 6: CDMO overview
CDMO overview 3 5 9 Molecule-to-market Technology Development and service offerings platforms manufacturing sites 6 1Q20 QUARTERLY SUPPLEMENT
Slide 7: CDMO COVID-19 partnerships
CDMO COVID-19 partnerships Novavax • Agreement provides clinical supply to support Phase 1 trial in May 2020 Vaxart • Agreement provides clinical supply to support Phase 1 trial in H2 2020 Johnson & Johnson • Agreement to be the manufacturer of drug substance, enables readiness and reservation of ce
Slide 8: COVID-19 Response: Hyperimmunes
COVID-19 Response: Laura Saward, Ph.D. Hyperimmunes Senior Vice President, Therapeutics Business Unit Head
Slide 9: Therapeutics experience
Therapeutics experience 40+ 6 Years of experience FDA-licensed products Proven on hyperimmune on the hyperimmune manufacturing development and platforms (human technology & manufacturing & equine) infrastructure 9 1Q20 QUARTERLY SUPPLEMENT
Slide 10: Development of a hyperimmune treatment
Development of a hyperimmune treatment 10 1Q20 QUARTERLY SUPPLEMENT
Slide 11: COVID-19 antibodies help to fight the infection
COVID-19 antibodies help to fight the infection Three Potential Mechanisms of Action: 1. Antibodies can help block binding of virus and its ability to replicate 2. Antibodies can help immune cells kill the virus 3. Antibodies can help speed up clearance of virus from the body 11 1Q20 QUARTERLY SUPPL
Slide 12: Development of a hyperimmune treatment
Development of a hyperimmune treatment 12 1Q20 QUARTERLY SUPPLEMENT
Slide 13: Expedited development pathway
Expedited development pathway GMP Manufacturing Clinical Emergency Use LotscGMP produced Manufacturing as soon as Phase 2 study PursueAuthorization Emergency (EUA Use) plasma collected in patientsClinical COVIDAuthorizationefficacy & safety (EUA data) Plasma Commercial Leverage Safety Expertise Manu
Slide 14: Financial Outlook
Financial Richard S. Lindahl Outlook Executive Vice President, Chief Financial Officer and Treasurer
Slide 15: Financial outlook highlights
Financial outlook highlights Solid 1Q20 financial 2020 full year 1 performance 4 guidance reaffirmed Responsibly confident in ability Strong liquidity position to sustain momentum in current 2 5 uncertain environment Tailwinds in CDMO business 3 mitigating softness in Travel Health 15 1Q20 QUARTERLY
Slide 16: Emergent delivers peace of mind in an uncertain world
Emergent delivers PEACE OF MIND in an uncertain world
Emergent BioSolutions — Q1 2020 Earnings Presentation on 6ix